Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study

Abdel‐Rahman, Omar

doi:10.1007/s00432-018-2610-z

Cited by 29 publications

(34 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although CT-PMWA is a kind of minimal invasive therapies, preoperative hepatic function reserve was significantly associated with the long-term prognosis of patients. Our findings were consistent with previous studies [18][19][20][21][22][23][24][25][26]. Therefore, the better patients' hepatic function reserve was assessed, the better patients' prognosis could be evaluated.…”

Section: Discussionsupporting

confidence: 92%

“…Pinato et al have validated the ALBI grade in a large, multicenter and international study, and the ALBI grade was confirmed to provide objective hepatic reserve estimation across each Barcelona Clinic Liver Cancer (BCLC) stage of HCC [22]. In addition, the ALBI grade was suggested as a significant predictor for the OS of HCC patients who underwent surgical resection, transarterial chemoembolization (TACE), or sorafenib [22][23][24][25][26]. Kao et al constructed a nomogram with ALBI grade to assess the OS of patients with early-stage HCCs after RFA, in which study the personalized long-term OS data were offered [27].…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Predictive value of the albumin-bilirubin grade on long-term outcomes of CT-guided percutaneous microwave ablation in intrahepatic cholangiocarcinoma

Zhang

et al. 2019

International Journal of Hyperthermia

View full text Add to dashboard Cite

2019) Predictive value of the albumin-bilirubin grade on long-term outcomes of CTguided percutaneous microwave ablation in intrahepatic cholangiocarcinomaABSTRACT Purpose: To assess the efficacy of the albumin-bilirubin (ALBI) grade on assessing long-term outcomes of computed tomography (CT)-guided percutaneous microwave ablation (CT-PMWA) in the treatment of patients with intrahepatic cholangiocarcinoma (ICC). Methods: Between April 2011 and March 2018, 78 patients who underwent CT-PMWA were enrolled in this study. Overall survival (OS) and recurrence-free survival (RFS) were compared in the groups stratified by the ALBI grade and Child-Pugh score. Cox proportional hazard regression analyses were performed to determine independent predictors of OS and RFS. Results: After a median follow-up of 22.7 months (range 1-86.7 months), 67 patients had died. The cumulative 1-, 3-, and 5-year OS rates were 89.5%, 52.2%, and 35.0%, respectively. Stratified by the ALBI grade, the cumulative 1-, 3-, and 5-year OS rates were 100%, 69.2%, and 25.6% for patients with the grade 1, respectively. For patients with the ALBI grade 2, the cumulative 1-, 3-, and 5-year OS rates were 41.0%, 10.3%, and 10.3%, respectively. Patients with a hepatic function of the ALBI grade 1 had significantly higher OS rates than patients with the ALBI grade 2 (p < .001). The multivariate analysis showed tumor size (Hazard Ratio[HR] 95% Confidence Interval[CI]:9.03[1.01-80.52], p ¼ .049) and the ALBI grade (HR[95%CI]:9.56[1.58-58.00], p ¼ .014) were associated with OS, and tumor size (HR: 2.03[0.69-8.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 96%

Predictive value of the albumin-bilirubin grade on long-term outcomes of CT-guided percutaneous microwave ablation in intrahepatic cholangiocarcinoma

Zhang

et al. 2019

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…In the sorafenib-based group, initially or non-initially treatment had no effect on OS and PFS. Several researchers indicated that proper therapies prior to sorafenib led to better survival outcomes for HCC patients (24,25). It implied that in the treatment strategy of advanced HCC, multiple combinations of locoreginal and systemic modalities treatment could be applied, which may have a beneficial therapeutic impact.…”

Section: Discussionmentioning

confidence: 99%

Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study

Mei

Wang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: Macroscopic vascular invasion (MVI) commonly occurs in patients with advanced hepatocellular carcinoma (HCC) for which resection and sorafenib are the common therapies prescribed. Here, we aimed to compare the survival outcomes of these two therapies in HCC patients with MVI. Methods: In total, 496 patients diagnosed with HCC and MVI without extrahepatic metastasis, treated with resection (resection-based group, n = 388) and sorafenib (sorafenib-based group, n = 108) were included in this study. A one-to-one propensity score-matching analysis (PSM) was performed to minimize the effect of potential confounders. Results: The median OS in the resection-and sorafenib-based group was 20.7 months (95% CI: 16.9-24.5) and 11.6 months (95% CI: 8.4-14.9) (p < 0.001), respectively. The median PFS was 4.7 months (95% CI: 3.8-5.5) in the resection-based group and 4.4 months (95% CI: 3.6-5.2) in the sorafenib-based group (p < 0.001). After PSM, 72 patients from each group were matched. The median OS was 27.2 months (95% CI: 16.4-38.0) in the resection-based group and 13.0 months (95% CI: 9.6-16.3) in the sorafenib-based group (p < 0.001). The median PFS was 5.3 months (95% CI: 3.2-7.4) in the resection-based group and 4.8 months (95% CI: 3.6-6.0) in the sorafenib-based group (p = 0.061). Conclusion: Findings from this study showed that, compared with sorafenib-based treatment, surgical resection might be associated with better survival benefits to HCC patients with MVI.

show abstract

“…Multivariate analysis identified ALBI grade 1 as a significant strong predictor of a high ORR, and it is associated with the lowest probability of treatment discontinuation because of adverse events (AEs) [42]. High-grade AEs were observed more frequently in patients with ALBI grade ≥2 in the sorafenib group of the SUN1120 trial [43]. Also, patients with ALBI grade 1 receiving sorafenib show significantly better OS than those with ALBI grade ≥2 [44].…”

Section: Methodsmentioning

confidence: 99%

A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

et al. 2020

View full text Add to dashboard Cite

show abstract

Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study

Abstract: Within a cohort of highly selected advanced HCC patients, baseline patient-, liver-, and disease-centered variables play an important role in predicting patient outcomes. This information is important in terms of therapeutic decision-making and patient counseling.

Cited by 29 publications

References 24 publications

Predictive value of the albumin-bilirubin grade on long-term outcomes of CT-guided percutaneous microwave ablation in intrahepatic cholangiocarcinoma

Predictive value of the albumin-bilirubin grade on long-term outcomes of CT-guided percutaneous microwave ablation in intrahepatic cholangiocarcinoma

Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study

A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

Contact Info

Product

Resources

About